| Primary |
| Multiple Myeloma |
36.7% |
| Plasma Cell Myeloma |
13.6% |
| Amyloidosis |
8.1% |
| Prophylaxis |
6.1% |
| Product Used For Unknown Indication |
5.9% |
| Bone Marrow Transplant |
3.5% |
| Stem Cell Transplant |
2.8% |
| Drug Use For Unknown Indication |
2.6% |
| Thrombosis Prophylaxis |
2.6% |
| Hypertension |
2.1% |
| Bone Marrow Conditioning Regimen |
2.0% |
| Acute Lymphocytic Leukaemia |
2.0% |
| Prophylaxis Against Graft Versus Host Disease |
1.9% |
| Non-hodgkin's Lymphoma |
1.9% |
| Malignant Melanoma |
1.7% |
| Pain |
1.6% |
| Bone Pain |
1.4% |
| Mantle Cell Lymphoma |
1.3% |
| Central Nervous System Lymphoma |
1.1% |
| Neuroblastoma |
1.1% |
|
| Pyrexia |
13.9% |
| Vomiting |
13.0% |
| Thrombocytopenia |
8.0% |
| Pneumonia |
7.1% |
| Toxicity To Various Agents |
6.3% |
| Venoocclusive Liver Disease |
5.9% |
| Refractory Cytopenia With Multilineage Dysplasia |
4.6% |
| Septic Shock |
4.2% |
| Febrile Neutropenia |
3.8% |
| Refractory Anaemia With An Excess Of Blasts |
3.4% |
| Sepsis |
3.4% |
| Vitreous Haemorrhage |
3.4% |
| White Blood Cell Count Decreased |
3.4% |
| Acute Myeloid Leukaemia |
2.9% |
| Blood Creatine Phosphokinase Increased |
2.9% |
| Engraftment Syndrome |
2.9% |
| Infection |
2.9% |
| Neutropenia |
2.9% |
| Hepatitis B |
2.5% |
| Renal Failure |
2.5% |
|
| Secondary |
| Multiple Myeloma |
28.8% |
| Plasma Cell Myeloma |
11.3% |
| Product Used For Unknown Indication |
11.2% |
| Prophylaxis Against Graft Versus Host Disease |
6.5% |
| Drug Use For Unknown Indication |
6.1% |
| Stem Cell Transplant |
5.7% |
| Prophylaxis |
5.2% |
| Bone Marrow Conditioning Regimen |
4.1% |
| Non-hodgkin's Lymphoma |
2.5% |
| Mantle Cell Lymphoma |
2.3% |
| Acute Myeloid Leukaemia |
2.2% |
| Cord Blood Transplant Therapy |
1.9% |
| Hypertension |
1.9% |
| Thrombosis Prophylaxis |
1.7% |
| Infection Prophylaxis |
1.6% |
| Diffuse Large B-cell Lymphoma |
1.6% |
| B-cell Lymphoma |
1.5% |
| Constipation |
1.3% |
| Acute Lymphocytic Leukaemia |
1.3% |
| Neuroblastoma |
1.3% |
|
| Myelodysplastic Syndrome |
8.4% |
| Pyrexia |
8.1% |
| Thrombocytopenia |
8.1% |
| Gastrointestinal Inflammation |
7.0% |
| Sepsis |
6.3% |
| Acute Myeloid Leukaemia |
6.0% |
| Death |
5.8% |
| Vomiting |
5.1% |
| Chronic Graft Versus Host Disease |
4.6% |
| Renal Failure Acute |
4.6% |
| Pneumonia |
4.3% |
| Septic Shock |
4.3% |
| Acute Graft Versus Host Disease |
4.0% |
| Infection |
3.9% |
| Transplant Failure |
3.7% |
| Venoocclusive Liver Disease |
3.3% |
| Graft Versus Host Disease |
3.1% |
| Multi-organ Failure |
3.1% |
| Renal Failure |
3.1% |
| White Blood Cell Count Decreased |
3.0% |
|
| Concomitant |
| Multiple Myeloma |
22.3% |
| Product Used For Unknown Indication |
15.2% |
| Drug Use For Unknown Indication |
9.8% |
| Plasma Cell Myeloma |
7.7% |
| Prophylaxis |
6.6% |
| Prophylaxis Against Graft Versus Host Disease |
6.6% |
| Bone Marrow Conditioning Regimen |
6.2% |
| Infection Prophylaxis |
5.3% |
| Premedication |
3.1% |
| Stem Cell Transplant |
2.8% |
| Hypertension |
2.1% |
| Cord Blood Transplant Therapy |
1.9% |
| Pain |
1.9% |
| Plasmacytoma |
1.5% |
| Acute Myeloid Leukaemia |
1.4% |
| Antifungal Prophylaxis |
1.3% |
| Chemotherapy |
1.2% |
| Non-hodgkin's Lymphoma |
1.1% |
| Graft Versus Host Disease |
1.0% |
| Mucosal Inflammation |
0.9% |
|
| Tooth Extraction |
12.4% |
| Thrombocytopenia |
7.4% |
| Osteonecrosis |
6.9% |
| Vomiting |
6.3% |
| Drug Ineffective |
6.2% |
| Weight Decreased |
5.9% |
| Wound Drainage |
5.4% |
| Sepsis |
5.1% |
| Pyrexia |
4.8% |
| Death |
4.2% |
| White Blood Cell Count Decreased |
4.2% |
| X-ray Abnormal |
4.1% |
| Pneumonia |
3.6% |
| Venoocclusive Liver Disease |
3.6% |
| Graft Versus Host Disease |
3.5% |
| Renal Failure |
3.5% |
| Stem Cell Transplant |
3.5% |
| Respiratory Failure |
3.2% |
| Stomatitis |
3.2% |
| Weight Increased |
3.0% |
|
| Interacting |
| Bone Marrow Conditioning Regimen |
62.5% |
| Prophylaxis Against Graft Versus Host Disease |
25.0% |
| Prophylaxis |
12.5% |
|
| Mucosal Inflammation |
60.0% |
| Pseudomonas Infection |
20.0% |
| Toxicity To Various Agents |
20.0% |
|
